Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Atai Life Sciences N.V. (NQ: ATAI )

1.805 -0.065 (-3.48%)
Streaming Delayed Price Updated: 10:30 AM EDT, Jun 8, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Atai Life Sciences N.V.

< Previous 1 2 3 Next >
atai Life Sciences to Participate in Upcoming June Investor Conferences
From atai Life Sciences
Via GlobeNewswire
atai Life Sciences Reports First Quarter 2023 Financial Results and Announces Pipeline Highlights and Updates
From atai Life Sciences
Via GlobeNewswire
atai Life Sciences to Participate in Upcoming May Investor Conference
From atai Life Sciences
Via GlobeNewswire
atai Life Sciences Presents Pharmacodynamic Data on GRX-917 in a Late Breaking Poster Presentation at the 2023 SOBP Annual Meeting
From atai Life Sciences
Via GlobeNewswire
atai Life Sciences Announces First Subject Dosed in the Phase 1 IV-to-Subcutaneous Bridging Study of PCN-101 (R-Ketamine)
From atai Life Sciences
Via GlobeNewswire
atai Life Sciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical Pipeline Highlights
From atai Life Sciences
Via GlobeNewswire
atai Life Sciences Announces Key Clinical Pipeline and Corporate Updates
From atai Life Sciences
Via GlobeNewswire
atai Life Sciences to Participate in the Cowen 43rd Annual Health Care Conference
From atai Life Sciences
Via GlobeNewswire
Psychedelic-Derived Medicines for Neurologic Conditions Fueling Large Revenue Growth in Projected $4 Billion Dollar Industry
EQNX::TICKER_START (OTCQB:LOBEF),(NASDAQ:ATAI),(NASDAQ:CMPS),(NYSE:CYBN),(NASDAQ:MNMD) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Economy
Exposures Supply Chain
atai Life Sciences Company GABA Therapeutics Announces Positive Final Results from Phase 1 Single and Multiple Ascending Dose Trial of GRX-917
From atai Life Sciences
Via GlobeNewswire
atai Life Sciences Announces Results from Phase 2a Trial of PCN-101 (R-ketamine) for Treatment-Resistant Depression
From atai Life Sciences
Via GlobeNewswire
atai Life Sciences Announces Results from the Kures Therapeutics Phase 1 Trial of KUR-101
From atai Life Sciences
Via GlobeNewswire
atai Life Sciences Initiates Phase 2b proof-of-concept trial of RL-007 for Cognitive Impairment Associated with Schizophrenia
From atai Life Sciences
Via GlobeNewswire
The atai Fellowship Fund in Psychedelic Neuroscience Announces its First Cohort at Massachusetts General Hospital
From atai Life Sciences
Via GlobeNewswire
atai Life Sciences Strengthens Leadership Team with Appointment of Dr. Sahil V. Kirpekar as Chief Business Officer
From atai Life Sciences
Via GlobeNewswire
atai Life Sciences and Massachusetts General Hospital Announce Initiation of Clinical Study Investigating Neuroplasticity Biomarkers in Treatment-Resistant Depression Patients Undergoing Ketamine Treatment
From atai Life Sciences
Via GlobeNewswire
Greater Prevalence of Anxiety & Depressive Disorders Driving Demand for New Anti-Anxiety Drug Candidates
EQNX::TICKER_START (NASDAQ:SAGE),NASDAQ:NERV),(NASDAQ:ATAI),(NYSE:CYBN),(TSXV:MRVL),(NEO:CYBN), EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Retirement
Exposures Pension Product Safety
atai Life Sciences Reports Third Quarter 2022 Financial Results and Business Update
From atai Life Sciences
Via GlobeNewswire
Women in Psychedelics Announces atai as Platinum Sponsors
From Women in Psychedelics Network
Via Business Wire
atai Life Sciences to Participate in November Investor Events & Healthcare Conferences
From atai Life Sciences
Via GlobeNewswire
atai Life Sciences to Announce Third Quarter 2022 Financial Results and Business Update
From atai Life Sciences
Via GlobeNewswire
atai Life Sciences Company, Perception Neuroscience, Completes Enrollment for Phase 2a Clinical Trial of PCN-101 (R-Ketamine) for Treatment-Resistant Depression
From atai Life Sciences
Via GlobeNewswire
atai Life Sciences Announces R&D Day Agenda
From atai Life Sciences
Via GlobeNewswire
atai Life Sciences Announces Initiation of Phase 1 Proof-of-Concept Clinical Trial for Its Sol-gel Based Direct-to-Brain Drug Delivery Technology
From atai Life Sciences
Via GlobeNewswire
atai Life Sciences Announces Positive Initial Results for Phase 1 Trial of KUR-101, an Oral Formulation of Mitragynine for OUD
From atai Life Sciences
Via GlobeNewswire
Psychedelic Drugs Prove Their Worth In Clinical Trials
Novel psychedelic drugs have continuously proven their worth in clinical trials. Just recently, one company revealed that it was in the process of finalizing its Phase 1 first-in-human clinical trial... 
Via PressReach
Colorado to Vote on Legalizing Psychoactives in November
Voters in Colorado will have a say in the legalization of psychedelic drugs this November as an initiative to legalize psilocybin mushrooms and other naturally occurring psychedelics appears on the... 
Via PressReach
Topics Supply Chain
Exposures Supply Chain
Scientists Are Studying Psychedelic Drug as a Possible Treatment for Alzheimer’s Disease
A Toronto-based biotech firm is developing a new psychedelic medicine to cure Alzheimer’s disease, announcing recently that it has gotten approval from Argentina’s regulators to begin a Phase ll... 
Via PressReach
Topics Cannabis
Exposures Cannabis
Scientists Are Studying Psychedelic Drug as a Possible Treatment for Alzheimer’s Disease
FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – October 5, 2022 – A Toronto-based biotech firm is developing a new psychedelic medicine to cure Alzheimer’s disease,... 
Via FinancialNewsMedia
Topics Cannabis
Exposures Cannabis
atai Life Sciences Announces First Subject Dosed in Phase 1 Trial of Buccal and IV VLS-01, a Synthetic Form of DMT
From atai Life Sciences
Via GlobeNewswire
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.